| Pair Name | Piperlongumine, Sorafenib | ||
| Phytochemical Name | Piperlongumine (PubChem CID: 637858 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Piperlongumine, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CDK1 | hsa983 | |
| Down-regulation | Expression | CPSF7 | hsa79869 | |
| Down-regulation | Expression | MKI67 | hsa4288 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Phosphorylation | PRKAA1 | hsa5562 | |
| In Vitro Model | HCCLM3 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_6832 |
| SMMC-7721 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0534 | |
| Result | Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer | |||
| No. | Title | Href |
|---|---|---|
| 1 | Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer. Pharmacol Res. 2022 Mar;177:106140. doi: 10.1016/j.phrs.2022.106140. | Click |
